evaluate the course of wet AMD in eyes undergoing phacoemulsification and previously treated with anti-VEGF injections. Methods: Records of patients ≥50 years with AMD who underwent uneventful phacoemulsification…
evaluate the efficacy of aflibercept in patients with diabetic macular edema unresponsive to anti-VEGF. Material & Methods: Retrospective chart review of patients with diabetic macular edema unresponsive to anti-VEGF…
growth factor (VEGF) family are well-known angiogenesis activators. Despite the promising activity of anti-VEGF agents in preclinical settings, these drugs appear to be insufficient for inhibiting tumor angiogenesis…
Though the pharmacokinetic profiles and retinochoroidal penetration of the 3 currently available antibody-based anti-VEGF molecules are incompletely defined, several important studies have formed the basis for much…
discovery of anti-VEGF drugs has revolutionized the management of age-related macular degeneration, diabetic macular oedema and retinal vein occlusion. This paper discusses how the management evolved
underwent 2 intravitreal injections of 0.5 mg ranibizumab at intervals of 1 month. Further, anti-VEGF therapy was performed in a "pro re nata" regimen. The control group consisted ... recovery of visual functions…
rheumatoid arthritis. Hence, blocking VEGF is the best way to prevent angiogenesis. An anti-VEGF, Fc-fusion protein, VEGFR1(D1-D3)- Fc, was developed in-house, using recombinant DNA technology ... thus inhibiting the…
elderly. The neo vascular form involves abnormal blood vessel growth under the retina. Anti-VEGF agents ranibizumab and aflibercept inhibit this growth and leakage. This randomized controlled trial compared their
endothelial growth factor (VEGF) is a key driver of vascular leakage in DME. An anti-VEGF therapy as a standard must be carefully monitored. The effectiveness and safety of this
anti-GBM disease affecting the kidney and eye. Our patient was successfully treated with anti-VEGF injections, the first time this has been described for this indication
mice. In this study, we evaluated the impact of the systemic administration of an anti-VEGF antibody on cognitive function, hippocampal vascularization, cerebral metabolic activity and hippocampal synaptic activity
mice. In this study, we evaluated the impact of the systemic administration of an anti-VEGF antibody on cognitive function, hippocampal vascularization, cerebral metabolic activity and hippocampal synaptic activity
novel intravitreal anti-VEGF therapy has revolutionized treatment of neovascular age-related macular degeneration (AMD). After promising outcomes of monthly injections reported by the ANCHOR ( AN ti-VEGF antibody